These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

517 related items for PubMed ID: 19152409

  • 1. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
    Cha CK, Kwon HC, Cheong JY, Cho SW, Hong SP, Kim SO, Yoo WD.
    J Med Virol; 2009 Mar; 81(3):417-24. PubMed ID: 19152409
    [Abstract] [Full Text] [Related]

  • 2. Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy.
    Lee YS, Chung YH, Kim JA, Kim SE, Shin JW, Kim KM, Lim YS, Park NH, Lee HC, Lee YS, Suh DJ.
    Liver Int; 2009 Apr; 29(4):552-6. PubMed ID: 19323782
    [Abstract] [Full Text] [Related]

  • 3. Response to adefovir depends on mutation patterns in precore region, basal core promoter and reverse transcriptase, and on-treatment responses in Lamivudine-resistant chronic hepatitis B patients.
    Song BC, Cui XJ, Shin JW, Park NH, Cho YK, Song HJ, Hyun S, Jeong SU, Choi EK, Kim HU.
    Intervirology; 2010 Apr; 53(4):203-10. PubMed ID: 20332649
    [Abstract] [Full Text] [Related]

  • 4. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients.
    Westland CE, Yang H, Delaney WE, Wulfsohn M, Lama N, Gibbs CS, Miller MD, Fry J, Brosgart CL, Schiff ER, Xiong S.
    J Viral Hepat; 2005 Jan; 12(1):67-73. PubMed ID: 15655050
    [Abstract] [Full Text] [Related]

  • 5. The influence of YMDD mutation patterns on clinical outcomes in patients with adefovir add-on lamivudine combination treatment.
    Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI.
    Liver Int; 2012 Feb; 32(2):303-10. PubMed ID: 22098177
    [Abstract] [Full Text] [Related]

  • 6. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
    Zaaijer HL, Takkenberg RB, Weegink CJ, Rebers SP, Menting S, Reesink HW, Schinkel J, Molenkamp R.
    J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408
    [Abstract] [Full Text] [Related]

  • 7. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
    Yang JX, Liu BM, Li XG, Yan CH, Xu J, Sun XW, Wang YH, Jiao XJ, Yan L, Dong JP, Hou CS, Abuduheilili X, Li T, Zhuang H.
    Antivir Ther; 2010 Mar; 15(8):1171-8. PubMed ID: 21149924
    [Abstract] [Full Text] [Related]

  • 8. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V.
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [Abstract] [Full Text] [Related]

  • 9. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.
    Choe WH, Hong SP, Kim BK, Ko SY, Jung YK, Kim JH, Yeon JE, Byun KS, Kim KH, Ji SI, Kim SO, Lee CH, Kwon SY.
    Antivir Ther; 2009 Jun; 14(7):985-93. PubMed ID: 19918102
    [Abstract] [Full Text] [Related]

  • 10. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
    Suzuki F, Kumada H, Nakamura H.
    J Med Virol; 2006 Aug; 78(8):1025-34. PubMed ID: 16789011
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Shim JH, Suh DJ, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS.
    Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
    [Abstract] [Full Text] [Related]

  • 12. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
    Dai CY, Chuang WL, Hsieh MY, Lee LP, Huang JF, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Tsai JF, Chang WY, Yu ML.
    Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
    [Abstract] [Full Text] [Related]

  • 13. [Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients].
    Cho JH, Cheong JY, Kang JK, Park JS, Lee MH, Lim NK, Hong SP, Kim SO, Yoo WD, Cho SW.
    Korean J Hepatol; 2008 Mar; 14(1):58-66. PubMed ID: 18367858
    [Abstract] [Full Text] [Related]

  • 14. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
    Li X, Liu Y, Zhao P, Wang Y, Chen L, Xin S, Zhang XX, Xu D.
    Antivir Ther; 2015 Mar; 20(2):141-7. PubMed ID: 24992206
    [Abstract] [Full Text] [Related]

  • 15. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ, Li SG, Wen FY, Yang XY, Wu JL, Tan B, Fu J.
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
    [Abstract] [Full Text] [Related]

  • 16. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients.
    Idilman R, Kaymakoglu S, Oguz Onder F, Ahishali E, Bektas M, Cinar K, Pinarbasi B, Karayalcin S, Badur S, Cakaloglu Y, Mithat Bozdayi A, Bozkaya H, Okten A, Yurdaydin C.
    J Viral Hepat; 2009 Apr; 16(4):279-85. PubMed ID: 19222742
    [Abstract] [Full Text] [Related]

  • 17. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M, Tamori A, Kohmoto MT, Morikawa H, Habu D, Sakaguchi H, Takeda T, Seki S, Kawada N, Shiomi S, Nishiguchi S.
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [Abstract] [Full Text] [Related]

  • 18. Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy.
    Chang UI, Lee YC, Wie SH, Jang JW, Bae SH, Choi JY, Yang JM, Yoon SK, Sun HS.
    J Med Virol; 2007 Jul; 79(7):902-10. PubMed ID: 17516533
    [Abstract] [Full Text] [Related]

  • 19. Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance.
    Cho SW, Koh KH, Cheong JY, Lee MH, Hong SP, Yoo WD, Kim SO.
    J Viral Hepat; 2010 Mar; 17(3):171-7. PubMed ID: 19678894
    [Abstract] [Full Text] [Related]

  • 20. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.
    Moriconi F, Colombatto P, Coco B, Ciccorossi P, Oliveri F, Flichman D, Maina AM, Sacco R, Bonino F, Brunetto MR.
    J Antimicrob Chemother; 2007 Aug; 60(2):341-9. PubMed ID: 17567633
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.